Enoxaparin Versus Unfractionated Heparin in PCI

Phase 4

Completed

• Conditions: Coronary Artery Disease

• Registration Number: NCT00439855
• Lead Sponsor: Triemli Hospital

Brief Summary

Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Detailed Description

Not available

Study Timeline

• Study Start: 2003-09
• Study Completion: 2006-02
• Status Verified: 2007-02
• Study First Submitted: 2007-02-23
• Study First Submitted QC: 2007-02-23
• Last Update Submitted: 2007-02-23
• Study First Posted: 2007-02-26
• Last Update Posted: 2007-02-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2100

Inclusion Criteria

• PCI for stable ischemia or ACS

Exclusion Criteria

• Cardiogenic shock,
• Pretreatment with study drugs,
• Lack of informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Quadruple endpoint: death, MI, urgent TVR, major bleeding

Secondary Outcome Measures

Name	Time	Method
major bleeding, minor bleeding, thrombocytopenia

Trial Locations

Locations (1)

Division of Cardiology Triemli Hospital Zurich; 🇨🇭 Zurich, Switzerland